133 related articles for article (PubMed ID: 27753013)
1. Detection of p53 Mutations in Circulating DNA of Transplanted Hepatocellular Carcinoma Patients as a Biomarker of Tumor Recurrence.
García-Fernández N; Macher HC; Rubio A; Jiménez-Arriscado P; Bernal-Bellido C; Bellido-Díaz ML; Suárez-Artacho G; Guerrero JM; Gómez-Bravo MA; Molinero P
Adv Exp Med Biol; 2016; 924():25-28. PubMed ID: 27753013
[TBL] [Abstract][Full Text] [Related]
2. Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing.
Liao W; Yang H; Xu H; Wang Y; Ge P; Ren J; Xu W; Lu X; Sang X; Zhong S; Zhang H; Mao Y
Oncotarget; 2016 Jun; 7(26):40481-40490. PubMed ID: 27248174
[TBL] [Abstract][Full Text] [Related]
3. INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas.
Tannapfel A; Busse C; Weinans L; Benicke M; Katalinic A; Geissler F; Hauss J; Wittekind C
Oncogene; 2001 Oct; 20(48):7104-9. PubMed ID: 11704835
[TBL] [Abstract][Full Text] [Related]
4. Close correlation between a p53 or hMSH2 gene mutation in the tumor and survival of hepatocellular carcinoma patients.
Yano M; Asahara T; Dohi K; Mizuno T; Iwamoto KS; Seyama T
Int J Oncol; 1999 Mar; 14(3):447-51. PubMed ID: 10024676
[TBL] [Abstract][Full Text] [Related]
5. Prediction of the prognosis of advanced hepatocellular carcinoma by TERT promoter mutations in circulating tumor DNA.
Hirai M; Kinugasa H; Nouso K; Yamamoto S; Terasawa H; Onishi Y; Oyama A; Adachi T; Wada N; Sakata M; Yasunaka T; Onishi H; Shiraha H; Takaki A; Okada H
J Gastroenterol Hepatol; 2021 Apr; 36(4):1118-1125. PubMed ID: 32830343
[TBL] [Abstract][Full Text] [Related]
6. Analysis of chromosomal instability in pulmonary or liver metastases and matched primary hepatocellular carcinoma after orthotopic liver transplantation.
Gross-Goupil M; Riou P; Emile JF; Saffroy R; Azoulay D; Lacherade I; Receveur A; Piatier-Tonneau D; Castaing D; Debuire B; Lemoine A
Int J Cancer; 2003 May; 104(6):745-51. PubMed ID: 12640682
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma.
Saffroy R; Lelong JC; Azoulay D; Salvucci M; Reynes M; Bismuth H; Debuire B; Lemoine A
Br J Cancer; 1999 Feb; 79(3-4):604-10. PubMed ID: 10027337
[TBL] [Abstract][Full Text] [Related]
8. SIRT1 regulates oncogenesis via a mutant p53-dependent pathway in hepatocellular carcinoma.
Zhang ZY; Hong D; Nam SH; Kim JM; Paik YH; Joh JW; Kwon CH; Park JB; Choi GS; Jang KY; Park CK; Kim SJ
J Hepatol; 2015 Jan; 62(1):121-30. PubMed ID: 25131770
[TBL] [Abstract][Full Text] [Related]
9. [p53 gene mutation in hepatocellular carcinoma].
Jiang W; Lu Q; Pan G
Zhonghua Wai Ke Za Zhi; 1998 Sep; 36(9):531-2. PubMed ID: 11825456
[TBL] [Abstract][Full Text] [Related]
10. Circulating tumor DNA profiling reveals clonal evolution and real-time disease progression in advanced hepatocellular carcinoma.
Cai ZX; Chen G; Zeng YY; Dong XQ; Lin MJ; Huang XH; Zhang D; Liu XL; Liu JF
Int J Cancer; 2017 Sep; 141(5):977-985. PubMed ID: 28543104
[TBL] [Abstract][Full Text] [Related]
11. A comparison between alpha-fetoprotein and p53 antibodies in the diagnosis of hepatocellular carcinoma.
Edis C; Kähler C; Klotz W; Herold M; Feichtinger H; Königsreiner A; Margreiter R; Jaschke W; Vogel W
Transplant Proc; 1998 May; 30(3):780-1. PubMed ID: 9595095
[No Abstract] [Full Text] [Related]
12. The p53 mutation spectrum in hepatocellular carcinoma from Guangxi, China : role of chronic hepatitis B virus infection and aflatoxin B1 exposure.
Qi LN; Bai T; Chen ZS; Wu FX; Chen YY; De Xiang B; Peng T; Han ZG; Li LQ
Liver Int; 2015 Mar; 35(3):999-1009. PubMed ID: 24461059
[TBL] [Abstract][Full Text] [Related]
13. High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations.
Peng SY; Chen WJ; Lai PL; Jeng YM; Sheu JC; Hsu HC
Int J Cancer; 2004 Oct; 112(1):44-50. PubMed ID: 15305374
[TBL] [Abstract][Full Text] [Related]
14. Mutation of p53 in recurrent hepatocellular carcinoma and its association with the expression of ZBP-89.
Chen GG; Merchant JL; Lai PB; Ho RL; Hu X; Okada M; Huang SF; Chui AK; Law DJ; Li YG; Lau WY; Li AK
Am J Pathol; 2003 Jun; 162(6):1823-9. PubMed ID: 12759240
[TBL] [Abstract][Full Text] [Related]
15. Serum tests for diagnosis and follow-up of hepatocellular carcinoma after treatment.
Trojan J; Raedle J; Zeuzem S
Digestion; 1998 Jul; 59 Suppl 2():72-4. PubMed ID: 9718428
[No Abstract] [Full Text] [Related]
16. Serum P53 Abs in HCC patients with viral hepatitis - type C.
EI-Emshaty HM; Gadelhak SA; Abdelaziz MM; Abbas AT; Gadelhak NA
Hepatogastroenterology; 2014 Sep; 61(134):1688-95. PubMed ID: 25436364
[TBL] [Abstract][Full Text] [Related]
17. microRNA-150: a promising novel biomarker for hepatitis B virus-related hepatocellular carcinoma.
Yu F; Lu Z; Chen B; Dong P; Zheng J
Diagn Pathol; 2015 Jul; 10():129. PubMed ID: 26215970
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma.
Gadelhak NA; Gadelhak SA; El-Morsi DA; Abdelaziz MM; Abbas AT; El-Emshaty HM
Hepatogastroenterology; 2009; 56(94-95):1417-24. PubMed ID: 19950803
[TBL] [Abstract][Full Text] [Related]
19. Use of specific ELISA for the detection of antibodies directed against p53 protein in patients with hepatocellular carcinoma.
Ryder SD; Rizzi PM; Volkmann M; Metivier E; Pereira LM; Galle PR; Naoumov NV; Zentgraf H; Williams R
J Clin Pathol; 1996 Apr; 49(4):295-9. PubMed ID: 8655704
[TBL] [Abstract][Full Text] [Related]
20. [A molecular pathological study of p53 gene in hepatocellular carcinoma].
Zhao P
Zhonghua Bing Li Xue Za Zhi; 1993 Feb; 22(1):16-8. PubMed ID: 8101139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
